CSTF2 Acts as a Prognostic Marker Correlated with Immune Infiltration in Hepatocellular Carcinoma

References

• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. doi:10.1038/nrdp.2016.18
   PubMed Web of Science ®Google Scholar
• Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450–1462. doi:10.1056/NEJMra1713263
   PubMed Web of Science ®Google Scholar
• Zheng R, Qu C, Zhang S, et al. Liver cancer incidence and mortality in China: temporal trends and projections to 2030. Chin J Cancer Res. 2018;30(6):571–579. doi:10.21147/j.issn.1000-9604.2018.06.01
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Galle P, Forner A, Llovet J, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol. 2017;34(2):153–159. doi:10.1053/j.semdp.2016.12.011
   PubMed Web of Science ®Google Scholar
• Darmon SK, Lutz CS. mRNA 3’ end processing factors: a phylogenetic comparison. Comp Funct Genomics. 2012;2012:876893. doi:10.1155/2012/876893
   PubMedGoogle Scholar
• Takagaki Y, Manley JL, MacDonald CC, et al. A multisubunit factor, CstF, is required for polyadenylation of mammalian pre-mRNAs. Genes Dev. 1990;4(12a):2112–2120. doi:10.1101/gad.4.12a.2112
   PubMed Web of Science ®Google Scholar
• Mandel CR, Bai Y, Tong L. Protein factors in pre-mRNA 3’-end processing. Cell Mol Life Sci. 2008;65(7–8):1099–1122. doi:10.1007/s00018-007-7474-3
   PubMed Web of Science ®Google Scholar
• Salisbury J, Hutchison KW, Graber JH. A multispecies comparison of the metazoan 3’-processing downstream elements and the CstF-64 RNA recognition motif. BMC Genomics. 2006;7(1):55. doi:10.1186/1471-2164-7-55
   PubMed Web of Science ®Google Scholar
• Takagaki Y, MacDonald CC, Shenk T, et al. The human 64-kDa polyadenylylation factor contains a ribonucleoprotein-type RNA binding domain and unusual auxiliary motifs. Proc Natl Acad Sci USA. 1992;89(4):1403–1407. doi:10.1073/pnas.89.4.1403
   PubMed Web of Science ®Google Scholar
• Youngblood BA, MacDonald CC. CstF-64 is necessary for endoderm differentiation resulting in cardiomyocyte defects. Stem Cell Res. 2014;13(3 Pt A):413–421. doi:10.1016/j.scr.2014.09.005
   PubMed Web of Science ®Google Scholar
• Grozdanov PN, Masoumzadeh E, Kalscheuer VM, et al. A missense mutation in the CSTF2 gene that impairs the function of the RNA recognition motif and causes defects in 3’ end processing is associated with intellectual disability in humans. Nucleic Acids Res. 2020;48(17):9804–9821. doi:10.1093/nar/gkaa689
   PubMed Web of Science ®Google Scholar
• Youngblood BA, Grozdanov PN, MacDonald CC. CstF-64 supports pluripotency and regulates cell cycle progression in embryonic stem cells through histone 3’ end processing. Nucleic Acids Res. 2014;42(13):8330–8342. doi:10.1093/nar/gku551
   PubMed Web of Science ®Google Scholar
• Takagaki Y, Seipelt RL, Peterson ML, et al. The polyadenylation factor CstF-64 regulates alternative processing of IgM heavy chain pre-mRNA during B cell differentiation. Cell. 1996;87(5):941–952. doi:10.1016/S0092-8674(00)82000-0
   PubMed Web of Science ®Google Scholar
• Chuvpilo S, Zimmer M, Kerstan A, et al. Alternative polyadenylation events contribute to the induction of NF-ATc in effector T cells. Immunity. 1999;10(2):261–269. doi:10.1016/S1074-7613(00)80026-6
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang JX, Luo JH, et al. CSTF2-induced shortening of the RAC1 3ʹUTR promotes the pathogenesis of urothelial carcinoma of the bladder. Cancer Res. 2018;78(20):5848–5862. doi:10.1158/0008-5472.CAN-18-0822
   PubMed Web of Science ®Google Scholar
• Lin A, Ji P, Niu X, et al. CstF64-induced shortening of the bid 3ʹUTR promotes esophageal squamous cell carcinoma progression by disrupting ceRNA cross-talk with ZFP36L2. Cancer Res. 2021;81(22):5638–5651. doi:10.1158/0008-5472.CAN-21-1201
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang X, Lei W, et al. Genome-wide profiling reveals alternative polyadenylation of mRNA in human non-small cell lung cancer. J Transl Med. 2019;17(1):257. doi:10.1186/s12967-019-1986-0
   PubMed Web of Science ®Google Scholar
• Aragaki M, Takahashi K, Akiyama H, et al. Characterization of a cleavage stimulation factor, 3’ pre-RNA, subunit 2, 64 kDa (CSTF2) as a therapeutic target for lung cancer. Clin Cancer Res. 2011;17(18):5889–5900. doi:10.1158/1078-0432.CCR-11-0240
   PubMed Web of Science ®Google Scholar
• Gharesouran J, Taheri M, Sayad A, et al. A novel regulatory function of long non-coding RNAs at different levels of gene expression in multiple sclerosis. J Mol Neurosci. 2019;67(3):434–440. doi:10.1007/s12031-018-1248-2
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Vasaikar SV, Straub P, Wang J, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956–D963. doi:10.1093/nar/gkx1090
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019;13(2):125–137. doi:10.1007/s12072-018-9919-1
   PubMed Web of Science ®Google Scholar
• Liu Z, Liu X, Liang J, et al. Immunotherapy for hepatocellular carcinoma: current status and future prospects. Front Immunol. 2021;12:765101. doi:10.3389/fimmu.2021.765101
   PubMed Web of Science ®Google Scholar
• Ye Y, Yu F, Li Z, et al. RNA binding protein serine/arginine splicing factor 1 promotes the proliferation, migration and invasion of hepatocellular carcinoma by interacting with RecQ protein-like 4 mRNA. Bioengineered. 2021;12(1):6144–6154. doi:10.1080/21655979.2021.1972785
   PubMed Web of Science ®Google Scholar
• Liang Y, Fan Y, Liu Y, et al. HNRNPU promotes the progression of hepatocellular carcinoma by enhancing CDK2 transcription. Exp Cell Res. 2021;409(1):112898. doi:10.1016/j.yexcr.2021.112898
   PubMed Web of Science ®Google Scholar
• Park S, Choi S, Cho YA, et al. Evaluation of the American Joint Committee on Cancer (AJCC) 8th edition staging system for hepatocellular carcinoma in 1008 patients with curative resection. Cancer Res Treat. 2020;52(4):1145–1152. doi:10.4143/crt.2020.208
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O. Assessment of the discriminating value of the 8th AJCC stage grouping for hepatocellular carcinoma. HPB. 2018;20(1):41–48. doi:10.1016/j.hpb.2017.08.017
   PubMed Web of Science ®Google Scholar
• Kamarajah SK, Frankel TL, Sonnenday C, et al. Critical evaluation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with Hepatocellular Carcinoma (HCC): a Surveillance, Epidemiology, End Results (SEER) analysis. J Surg Oncol. 2018;117(4):644–650. doi:10.1002/jso.24908
   PubMed Web of Science ®Google Scholar
• Wei Y, Luo H, Yee PP, et al. Paraspeckle protein NONO promotes TAZ phase separation in the nucleus to drive the oncogenic transcriptional program. Adv Sci. 2021;8(24):2102653. doi:10.1002/advs.202102653
   Web of Science ®Google Scholar
• Shen M, Zhang R, Jia W, et al. Nuclear scaffold protein p54nrb/NONO facilitates the hypoxia-enhanced progression of hepatocellular carcinoma. Oncogene. 2021;40(24):4167–4183. doi:10.1038/s41388-021-01848-9
   PubMed Web of Science ®Google Scholar
• Okada M, Cheeseman IM, Hori T, et al. The CENP-H–I complex is required for the efficient incorporation of newly synthesized CENP-A into centromeres. Nat Cell Biol. 2006;8(5):446–457. doi:10.1038/ncb1396
   PubMed Web of Science ®Google Scholar
• Ding N, Li R, Shi W, et al. CENPI is overexpressed in colorectal cancer and regulates cell migration and invasion. Gene. 2018;674:80–86. doi:10.1016/j.gene.2018.06.067
   PubMed Web of Science ®Google Scholar
• Wang J, Liu X, Chu H, et al. Centromere protein I (CENP-I) is upregulated in gastric cancer, predicts poor prognosis, and promotes tumor cell proliferation and migration. Technol Cancer Res Treat. 2021;20:1180552969. doi:10.1177/15330338211045510
   Web of Science ®Google Scholar
• Thangavelu PU, Lin C, Vaidyanathan S, et al. Overexpression of the E2F target geneCENPI promotes chromosome instability and predicts poor prognosis in estrogen receptor-positive breast cancer. Oncotarget. 2017;8(37):62167–62182. doi:10.18632/oncotarget.19131
   PubMedGoogle Scholar
• Yu Q, Yin L, Jian Y, et al. Downregulation of PHF6 inhibits cell proliferation and migration in hepatocellular carcinoma. Cancer Biother Radiopharm. 2019;34(4):245–251. doi:10.1089/cbr.2018.2671
   PubMed Web of Science ®Google Scholar
• Yu Q, Zhou J, Jian Y, et al. MicroRNA‐214 suppresses cell proliferation and migration and cell metabolism by targeting PDK2 and PHF6 in hepatocellular carcinoma. Cell Biol Int. 2019;44(1):117–126. doi:10.1002/cbin.11207
   PubMed Web of Science ®Google Scholar
• Romeo V, Griesbach E, Schümperli D. CstF64: cell cycle regulation and functional role in 3′ end processing of replication-dependent histone mRNAs. Mol Cell Biol. 2014;34(23):4272–4284. doi:10.1128/MCB.00791-14
   PubMed Web of Science ®Google Scholar
• Leone V, Ali A, Weber A, et al. Liver inflammation and hepatobiliary cancers. Trends Cancer. 2021;7(7):606–623. doi:10.1016/j.trecan.2021.01.012
   PubMed Web of Science ®Google Scholar
• Chen H, Zhou X, Li J, et al. Neutrophils: driving inflammation during the development of hepatocellular carcinoma. Cancer Lett. 2021;522:22–31. doi:10.1016/j.canlet.2021.09.011
   PubMed Web of Science ®Google Scholar
• Kim CG, Kim C, Yoon SE, et al. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. J Hepatol. 2021;74(2):350–359. doi:10.1016/j.jhep.2020.08.010
   PubMed Web of Science ®Google Scholar
• Zhong M, Zhong C, Cui W, et al. Induction of tolerogenic dendritic cells by activated TGF-β/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells. BMC Cancer. 2019;19(1):439. doi:10.1186/s12885-019-5670-9
   PubMed Web of Science ®Google Scholar
• Zhou Z, Xin H, Li J, et al. Intratumoral plasmacytoid dendritic cells as a poor prognostic factor for hepatocellular carcinoma following curative resection. Cancer Immunol Immunother. 2019;68(8):1223–1233. doi:10.1007/s00262-019-02355-3
   PubMed Web of Science ®Google Scholar
• Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29–39. doi:10.1016/j.intimp.2018.06.001
   PubMed Web of Science ®Google Scholar
• Zheng Y, Wang S, Cai J, et al. The progress of immune checkpoint therapy in primary liver cancer. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188638. doi:10.1016/j.bbcan.2021.188638
   PubMed Web of Science ®Google Scholar
• Wen X, Wu Y, Awadasseid A, et al. New advances in canonical wnt/beta-catenin signaling in cancer. Cancer Manag Res. 2020;12:6987–6998. doi:10.2147/CMAR.S258645
   PubMed Web of Science ®Google Scholar
• Xu C, Xu Z, Zhang Y, et al. beta-catenin signaling in hepatocellular carcinoma. J Clin Invest. 2022;132(4). doi:10.1172/JCI154515.
   Web of Science ®Google Scholar
• Zi Y, Gao J, Wang C, et al. Pantothenate kinase 1 inhibits the progression of hepatocellular carcinoma by negatively regulating Wnt/beta-catenin Signaling. Int J Biol Sci. 2022;18(4):1539–1554. doi:10.7150/ijbs.67842
   PubMed Web of Science ®Google Scholar